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Introduction: The aim of this study was to identify and characterize subclinical synovitis in patients with
rheumatoid arthritis (RA) in clinical remission using power Doppler ultrasound (PDUS) and serum levels of
biomarkers of inflammation and/or angiogenesis.
Methods: We selected patients with RA in clinical remission defined as a Disease activity score of 28 joints
(DAS28)-erythrocyte sedimentation rate (ESR) <2.6 for more than six months tested by two independent
rheumatologists. Clinical, epidemiological, demographic and serological data were analyzed. PDUS of knees and
hands was performed by a sonographer. Synovial hypertrophy (SH) and PDUS signal were scored (grades 0 to 3).
SH ≥2 and a PDUS signal was classified as active synovitis. Serum levels of biomarkers of inflammation/
angiogenesis were determined by Quantibody® Human Array.
Results: This study included 55 patients, of whom 25 (45.4%) met criteria for ultrasound-defined active synovitis.
Patients with active synovitis had higher DAS28-C reactive protein (P = 0.023), DAS28-ESR (P = 0.06), simplified
disease activity score, SDAI (P = 0.064), and only 12% were taking oral glucocorticoids (≤5 mg/day) compared with
40% of patients without active synovitis (P = 0.044). Patients with synovitis also had significantly higher serum levels
of the angiogenic biomarkers angiopoietin-2 (P = 0.038), vascular endothelial growth factor-D (P = 0.018), placental
growth factor (P = 0.043), stromal cell-derived factor-1 (P = 0.035), matrix metallopeptidase-2 (P = 0.027) and basic
fibroblast growth factor (bFGF) (P = 0.007), but not of pro-inflammatory cytokines.
In the multivariate logistic regression model used to explore prognostic biomarkers for active synovitis, serum levels
of bFGF, DAS28-ESR and not receiving glucocorticoids were the best predictors of active synovitis. The predictive
indexes provided by the model were specificity 73.3%, sensitivity 72%, and area under the curve in receiver
operating characteristic 81.5% (95% CI: 70.1% to 92.8%).
Conclusions: Nearly half of the patients with RA in clinical remission had ultrasound-defined active synovitis, higher
disease activity and less frequent oral glucocorticoid consumption than patients without active synovitis. This clinical
situation was associated with a specific biological profile characterized by an excess of angiogenic mediators rather
than persistent proinflammatory cytokine responses.* Correspondence: jcanete@clinic.ub.es
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Rheumatoid arthritis (RA) is a chronic inflammatory
immune-mediated disease characterized by polyarticular
synovitis that can lead to joint destruction with impair-
ment of function and quality of life. Current biologic
therapies and the implementation of treat-to-target stra-
tegies make remission an affordable goal. In fact, rates of
remission of RA of around 50% can be achieved if inten-
sive treatment is started in the early stages of the disease
[1]. However, there is concern about whether current cri-
teria reflect true remission characterized by the abrogation
of synovitis and, consequently, a lack of radiographic pro-
gression [2].
In recent years, ultrasound and magnetic resonance
imaging techniques have revealed that a significant per-
centage of patients classified as being in clinical remis-
sion exhibit different grades of synovitis, and a subgroup
of these patients suffer flares and/or joint damage during
follow-up [3-6].
One of the most conspicuous signs of synovitis is the
increase in synovial vascularization due to angiogenesis,
which is crucial for synovial growth and invasiveness [7].
Despite clinical improvement, the persistence of synovial
vascularization, evaluated by power Doppler ultrasound
(PDUS), has been associated with a higher risk of flares
and joint damage [8,9].
Although studies have aimed to correlate PDUS activity
in RA with cytokines implicated in angiogenesis, especially
vascular endothelial growth factor (VEGF), there are no
studies on the association between active synovitis as
defined by PDUS and angiogenic mediators in patients
with RA in clinical remission [10,11].
The objective of this study was to identify and cha-
racterize subclinical synovitis in patients with RA in
clinical remission using PDUS and to characterize the bio-
logical profile of this group of patients by determining in-
flammatory and angiogenic biomarkers.Patients and methods
Patients
Patients with RA in clinical remission for >6 months, as de-
fined by a 28-joint Disease Activity Score (DAS28)-erythro-
cyte sedimentation rate (ESR) <2.6 and confirmed by two
independent rheumatologists, were consecutively selected
from our Arthritis Unit outpatient clinic. Clinical, demo-
graphic and serological data were collected, including
low-dose oral prednisone treatment, disease-modifying
antirheumatic drugs and biological therapy. Rheumatoid
factor (RF) was determined by nephelometry and anti-
citrullinated peptide/protein antibodies (ACPA) by anti-
cyclic citrullinated peptide enzyme-linked immunosorbent
assay kits (Immunoscan; Eurodiagnostica, Malmö, Sweden
– distributed by Diasorin, Madrid, Spain). Signed informconsent was obtained from all patients. The study was ap-
proved by the Ethics Committee of the Hospital Clinic.
Methods
All sonographic assessments were performed using high-
sensitivity ultrasound equipment (Acuson Antares®; Siemens
AG, Erlangen, Germany). Sonographic assessments were
performed using a frequency range from 8 to 12 MHz.
Joint ultrasound findings were defined according to pub-
lished OMERACT definitions [12]. The frequency was
adapted to each joint assessed. A high frequency (12 MHz)
was used in superficial joints such as the metacarpophalan-
geal (MCP) or the proximal interphalangeal, and a lower
frequency (8 to 10 MHz) was used in the knees.
An experienced sonographer who was unaware of the
results of the clinical joint examination evaluated both
knees and 11 joints of each hand (including the proximal
interphalangeal joints, the MCP joints and the wrists)
for both synovial hypertrophy (SH) and intra-articular
PDUS signals according to EULAR guidelines [13]. All
joints evaluated were scanned for SH and PDUS on the
dorsal aspect (except for the knee, where the suprapa-
tellar and lateral and medial parapatellar recesses were
evaluated in the anterior aspect with the knee in exten-
sion) using longitudinal midline and transversal planes.
The wrists were additionally examined using longitu-
dinal dorso-radial and dorso-ulnar scans.
Synovial PDUS was assessed by selecting a region of
interest that included the bony margins, joint space and a
variable view of surrounding tissues. PDUS calibrations
were adjusted at the lowest permissible pulse-repetition fre-
quency to maximize sensitivity (500 to 800 Hz). The Dop-
pler frequency was set higher for the study of small joints
and superficial tissues, and lower for deep structures like
the knee. Color gain was set just below the level that causes
the appearance of noise artifacts. The sonographer was
allowed to modify the machine setting (for example, gain,
pulse-repetition frequency) in order to produce the best
quality images, allowing each image to be scored
appropriately.
SH and PDUS were graded using a four-grade se-
miquantitative scoring system from 0 to 3 (grade 0 = no, 1
=mild, 2 =moderate and 3 = severe) according to the
method developed by Szkudlarek and colleagues [14]. The
highest SH and PDUS grade detected during the scans was
adopted as representative of each joint, respectively. This
method was adapted to the knee ultrasound assessment
(SH: grade 0 = no; 1 =mild, flat thickened synovium; 2 =
moderate, thickened synovium with few villi-like protru-
sions; 3 = severe, marked thickening with multiple villi-like
protrusions; and PDUS: grade 0 = no flow in the synovium,
1 = single vessel signals, 2 = confluent vessel signals in less
than half the area of the synovium, 3 = vessel signals in
more than half the area of the synovium).
Ramírez et al. Arthritis Research & Therapy 2014, 16:R5 Page 3 of 10
http://arthritis-research.com/content/16/1/R5To ensure a stringent definition of synovitis by ultra-
sound, only patients with SH grade ≥2 plus PDUS signal
were classified as having active synovitis. If any assessed
joint met these criteria, the patient was classified as having
active synovitis. Examples of joints fulfilling these criteria
are shown in Figure 1.
Intra-rater agreement was 0.81 for SH and 0.92 for
PDUS. We made a double ultrasound assessment in the
first 10 patients included in the study. The two evaluations
were separated by between 24 and 72 hours. The same so-
nographer made both ultrasound explorations and noted
the results. This index was calculated as the percentage of
agreement between these scores at two time points. The
following cutoff values, analogous to kappa coefficients,
were defined for intra-rater reliability: <0.0 = none, 0 to
0.20 = poor, 0.21 to 0.40 =modest, 0.41 to 0.60 = fair, 0.61
to 0.80 = good and 0.81 to 1.00 = excellent.
Quantification of biomarkers of inflammation/
angiogenesis
Cytokines and angiogenic mediators were analyzed using
Quantibody® Human Custom Array (RayBiotech, Norcross,
GA, USA), which includes: activin A, angiopoietin (ANG),
ANG-1, ANG-2, angiostatin, angiopoietin-like protein-4
(ANGPTL4), basic fibroblast growth factor (bFGF), trans-
forming growth factor beta-1, placental growth factor
(PlGF), VEGF, VEGF-D, vascular endothelial growth factor
receptor (VEGFR)-1, VEGFR-2, tyrosine kinase with
immunoglobulin-like and endothelial growth factor-likeFigure 1 Representative images of ultrasound-defined synovitis in as
hypertrophy (SH) grade 2 and power Doppler ultrasound (PDUS) signal gra
and PDUS signal grade 2. (C) Knee joint: parapatellar recess, transversal view
longitudinal view: SH grade 2 and PDUS signal grade 3.domains-1 (Tie-1), tyrosine-kinase with immunoglobulin-
like and EGF-like domains-2 (Tie-2), epithelial cell-derived
neutrophil-activating peptide-78 (ENA-78), Growth Related
Oncogene (GRO), stromal-cell derived factor-1 (SDF-1),
CC-chemokine ligand (CXCL)-16, tumor necrosis factor
alpha (TNFα), interleukin (IL)-6, IL-8, IL-17A, IL-17 F,
IL-18, IL-20, IL-23, IL-33, matrix metalloproteinase
(MMP)-2, and MMP-9, according to the manufacturer’s
specifications. Each sample was diluted twofold and prepared
in quadruplicate. An Axon scanner 4000B with GenePix
software (Molecular Devices, Sunnyvalley, California, USA)
was used to collect fluorescence intensities. Detection limits
for cytokines are displayed on themanufacturer’s website [15].
After sample dilution, the effect of RF on the final results was
estimated to be around 1% [16].
Statistical analysis
Clinical variables, biomarkers and rates of therapeutic drugs
were compared between patients with and without synovitis.
The analysis was performed using the Mann–Whitney test
and 95% median confidence interval (CI; Hodges–Lehmann)
or the chi-square test, Fisher’s exact test and relative
risk estimation with 95% CIs. Associations between bio-
marker concentrations and other clinical variables were
studied using Spearman’s nonparametric correlation and the
Mann–Whitney test.
Prognostic factors for synovitis were analyzed in a
multivariate logistic regression model. Biomarkers were
transformed using the binary logarithm. Variables withsessed joints. (A) Radiocarpal joint, longitudinal view: synovial
de 3. (B) Proximal interphalangeal joint, longitudinal view: SH grade 2
: SH grade 2 and PDUS signal grade 2. (D) Metacarpophalangeal joint,
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ation) were included in the multivariate analysis. The
best predictive model was selected using R library
‘glmulti’ [17]. The final model selected had the low-
est Akaike information criteria. The odds ratios and
95% CIs, P values for selected prognostic factors,
model P values, MC Fadden R2, specificity, sensibil-
ity, predictive values and the area under the receiver
operating curve from the final model were
calculated.
For all tests, P ≤0.05 was considered significant. The
statistical analysis was made using the R statistical pro-
gram, version 3.0 [17].
Results
Clinical, demographic and serological characteristics
Fifty-five patients with RA in remission (76% female)
aged (median) 52 years were included; disease dur-
ation at inclusion was 90 months and remissionTable 1 Clinical, demographic and serologic data of 55 patien
All (n = 55)
Age (years) 52.0 (44.0 to 61.5) 5
Sex (male) 13 (23.6%)
Body mass index 25.2 (23.2 to 28.3) 2
Disease duration (months) 90.0 (57.1 to 148.9) 8
Remission duration (months) 37 (8 to 58) 2
DAS28-ESR 2.03 (1.67 to 2.44) 2
DAS28-CRP 1.42 (1.38 to 1.58) 1
SDAI 4.51 (3.56 to 6.21) 5
Patient global assessment 30 (10 to 30)
Physician global assessment 10 (10 to 30)
VAS pain 9 (2 to 25)
VAS fatigue 15 (2 to 47)
mHAQ 0.1 (0.0 to 0.3)
ESR (mm/1 hour) 9 (7 to 15)
CRP (mg/dl) 0.10 (0.03 to 0.33) 0
Rheumatoid factor 39 (71%)
Rheumatoid factor (IU) 103 (22 to 229)
ACPA 47 (86%)
ACPA titers (IU/ml) 254 (109 to 1575) 2
Prednisone 15 (27%)
DMARDs 45 (82%)
Biological therapy 23 (42%)
SH (grade ≥2) 31 (56%)
PDUS 35 (64%)
Data expressed as median (interquartile range) or as number (percentage). ACPA, anti-
28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, er
PDUS, power Doppler ultrasound; SDAI, Simplified Disease Activity Index; SH, synovialduration was 37 months; 71% were RF-positive and
86% were ACPA-positive; C-reactive protein (CRP)
was 0.10 mg/dl, ESR was 9, DAS28-ESR was 2.03,
DAS28-CRP was 1.42, Simplified Disease Activity
Index was 4.5, and modified Health Assessment
Questionnaire score was 0.1 (see Table 1).
Fifteen (27%) patients were taking low-dose oral
prednisone (dose ≤5 mg /day), 45 (82%) patients
disease-modifying antirheumatic drugs (95% metho-
trexate), and 23 (42%) patients biological therapies
(Table 1).
Power Doppler ultrasound findings
Eighty-nine percent of the patients had SH (grade 1 in-
cluded) in at least at one joint, and 64% had a PDUS
signal, mainly in the wrist (34.4% right; 32.7% left), se-
cond MCP (8.6% right; 6.8 left) and knees (5.1% right;
8.6% left).ts with and without synovitis
Ultrasound-defined active synovitis P valuea
Yes (n = 25) No (n = 30)
1.0 (44.0 to 59.0) 55.0 (47.0 to 63.3) 0.279
8 (32.0%) 5 (16.7%) 0.311
6.0 (24.0 to 29.0) 24.0 (23.1 to 27.4) 0.122
6.3 (60.3 to 153.8) 93.7 (54.9 to 145.2) 0.659
9 (7.50 to 50.00) 37 (9.00 to 66.25) 0.537
.24 (1.94 to 2.55) 1.92 (1.56 to 2.16) 0.060
.54 (1.39 to 1.67) 1.40 (1.23 to 1.48) 0.023
.03 (4.11 to 7.70) 4.14 (2.69 to 6.02) 0.064
30 (10 to 30) 30 (10 to 30) 0.767
10 (10 to 30) 10 (10 to 30) 0.322
14 (4 to 23) 5 (2 to 25) 0.251
14 (0 to 43) 16 (3 to 57) 0.529
0.1 (0.0 to 0.3) 0.0 (0.0 to 0.3) 0.570
10 (7 to 20) 9 (6 to 12) 0.498
.11 (0.03 to 0.49) 0.09 (0.04 to 0.23) 0.728
18 (72%) 21 (70%) 0.900
84 (22 to 240) 113 (23 to 215) 0.980
23 (92%) 24 (80%) 0.383
70 (121 to 1352) 226 (83 to 1600) 0.645
3 (12%) 12 (40%) 0.044
22 (88%) 23 (77%) 0.463
9 (36%) 14 (47%') 0.600
25 (100%) 6 (20%) <0.001
25 (100%) 10 (33%) <0.001
cyclic citrullinated peptide/protein antibody; CRP, C-reactive protein; DAS28,
ythrocyte sedimentation rate; mHAQ. Modified Health Assessment Questionnaire;
hypertrophy; VAS, visual analog scale. aMann–Whitney test.
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treatment in patients with ultrasound-defined active
synovitis
Twenty-five (45.4%) patients met the criteria for ultra-
sound-defined active synovitis. These patients had higher
DAS28-CRP (P = 0.023), DAS28-ESR (P = 0.06) and Sim-
plified Disease Activity Index (P = 0.064) scores. A signifi-
cantly lower percentage of patients with active synovitis
were in treatment with oral steroids (≤5 mg/day) com-
pared with patients without active synovitis (P = 0.044).
No differences in remission duration or in other clinical,Table 2 Biomarkers in patients with and without ultrasound-d
All (n = 55)
Yes (n
Activin A 6,556 (3,012 to 10,887) 9,186 (4,846
ANG 7,670 (6,206 to 10,496) 8,009 (6,729
ANG-1 32,622 (28,287 to 36,705) 34,343 (28,61
ANG-2 726.4 (595.8-1014.8) 881 (670
Angiostatin 37,409 (30,333 to 48,183) 34,326 (28,12
ANGPTL4 15,120 (6,450 to 6,464) 1,374 (606
bFGF 314 (268 to 492) 384 (288
CXCL16 849 (739 to 1,311) 907 (774
ENA-78 1,186 (813 to 1,746) 1,146 (871
GRO 9,570 (7,592 to 12,000) 10,724 (8,64
IL-17 10 (0 to 27) 13 (5
IL-17 F 288 (57 to 4,888) 344 (59 t
IL-18 589 (395 to 1,066) 741 (463
IL-20 259 (92 to 836) 422 (145
IL-23 249 (176 to 431) 257 (219
IL-33 14 (4 to 73) 17 (4
IL-6 149 (93 to 290) 177 (106
IL-8 30 (21 to 62) 42 (21
MMP-2 2,738 (1,941 to 4,050) 3,762 (2,29
MMP-9 28,180 (21,104 to 34,808) 27,370 (23,52
PlGF 288 (148 to 979) 453 (192
SDF-1 280 (117 to 1,554) 750 (164
TGF-β1 1,453 (809 to 2,252) 1,741 (1,06
Tie-1 5,099 (1,647 to 19,737) 6,841 (1,896
Tie-2 14,735 (6,215 to 32,401) 20,559 (7,42
TNFα 6,755 (4,460 to 12,112) 6,755 (4,539
VEGF 1,193 (815 to 1,990) 1,193 (871
VEGFR-1 485 (308 to 881) 634 (366
VEGFR-2 1,014 (713 to 1,918) 1,096 (869
VEGF-D 32,097 (17,815 to 227,618) 63,480 (26,77
Data expressed as median (interquartile range). ANG, angiopoietin; ANGPTL4, angiopo
ligand; ENA-78, epithelial cell-derived neutrophil-activating peptide-78; GRO, growth-re
growth factor; SDF-1, stromal-cell derived factor-1; TGF-β1, transforming growth factor
factor-like domains; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial grow
aMann–Whitney test.biological, serological or treatment differences were found
between groups (Table 1).
Ultrasound-defined active synovitis is associated with
higher serum levels of angiogenic biomarkers
Patients with active synovitis had significantly higher
serum levels of angiogenic biomarkers thought to be rele-
vant to RA pathogenesis, including VEGF-D (P = 0.018),
ANG-2 (P = 0.038), PlGF (P = 0.043), SDF-1 (P = 0.035),
MMP-2 (P = 0.027) and bFGF (P = 0.007) (Table 2 and
Figure 2). However, no association or correlations wereefined synovitis
Ultrasound-defined active synovitis P valuea
= 25) No (n = 30)
to 12,297) 4,175 (2,450 to 10,255) 0.086
to 10,816) 6867 (5,861 to 9,421) 0.119
5 to 39,515) 31,066 (27,977 to 35,834) 0.210
to 1,072) 702 (536 to 869) 0.038
3 to 46,416) 39,648 (34,243 to 49,152) 0.111
to 6,030) 2,294 (7,450 to 7,713) 0.630
to 675) 295 (265 to 318) 0.007
to 1,214) 848 (682 to 1,454) 0.967
to 1,664) 1,241 (780 to 1,886) 0.927
4 to 12,000) 9,284 (7,050 to 12,000) 0.350
to 32) 7 (0 to 25) 0.141
o 3,351) 204 (58 to 4,980) 0.872
to 1,224) 514 (341 to 890) 0.066
to 924) 234 (68 to 727) 0.098
to 699) 240 (166 to 323) 0.098
to 69) 11 (4 to 83) 0.866
to 317) 136 (91 to 226) 0.136
to 64) 26 (22 to 46) 0.366
4 to 5,574) 2,404 (1,915 to 3,263) 0.027
6 to 34,009) 29,008 (17,682 to 35,779) 0.940
to 1,357) 237 (117 to 721) 0.043
to 3,305) 165 (84 to 1,006) 0.035
5 to 2,424) 1,196 (649 to 2,053) 0.089
to 31,161) 4,039 (1,556 to 12,210) 0.112
6 to 47,483) 11,436 (4,101 to 26,744) 0.317
to 12,869) 6,362 (4,379 to 10,507) 0.465
to 2,178) 1,193 (810 to 1,911) 0.609
to 1,001) 471 (278 to 723) 0.204
to 1,807) 1,005 (679 to 1,937) 0.149
6 to 600,000) 27,545 (12,517 to 76,119) 0.018
ietin-like protein-4; bFGF, basic fibroblast growth factor; CXCL, CC-chemokine
lated oncogene; IL, interleukin; MMP, matrix metalloproteinase; PlGF, placental
beta-1; Tie, tyrosine-kinase with immunoglobulin-like and endothelial growth
th factor; VEGFR, vascular endothelial growth factor receptor.
Figure 2 Serum biomarkers differentially expressed in patients with and without ultrasound-defined synovitis. ANG, angiopoietin; bFGF,
basic fibroblast growth factor; MMP, matrix metalloproteinase; PlGF, placental growth factor; SDF-1, stromal-cell derived factor-1; VEGF, vascular
endothelial growth factor. CI, confidence interval; IQR, interquartile range.
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kines (TNFα, IL-6, IL-8, IL-17A, IL-17 F, IL-18, IL-20,
IL-23, and IL-33) (Table 3).
Correlations between biomarkers of inflammation/
angiogenesis and other clinical and sonographic variables
Ultrasound variables
SH grade ≥2 correlated with MMP-2 and transforming
growth factor beta-1 and showed a strong trend to
correlation with bFGF levels (Table 3). Interestingly, all
these mediators can be produced by synovial stromal
cells and infiltrating leukocytes, whereas a PDUS signal
only correlated, and negatively, with levels of angiostatin,
an inhibitor of angiogenesis. In addition, a strong trend
to correlation between the PDUS signal and bFGF was
found. These results suggest that bFGF is the only angio-
genic mediator differentially expressed both in relevant
synovial hypertrophy grade >2 and in synovial mem-
brane with positive PDUS (Table 3).
Inflammation and disease activity
CRP levels strongly correlated with ANGPTL4, chemokines
(CXCL16) and several proinflammatory cytokines (IL-17 F
and IL-33), whereas disease activity correlated with epithe-
lial cell-derived neutrophil-activating peptide-78, ANG and
VEGFR-1. Globally, these findings reflect the expected cor-
relation between systemic markers of inflammation and
proinflammatory cytokines levels (Table 3).
Autoantibodies
ACPA and RF titers strongly correlated with serum levels
of several biomarkers (Table 3). When only RF-negative
patients were analyzed (n = 16), the correlations between
ACPA titers (n = 11) and serum levels of angiogenic
factors were maintained. Moreover, RF-negative patients
with ultrasound-defined active synovitis had significantly
higher serum levels of several angiogenic factors than
patients without active synovitis (data not shown).Basic fibroblast growth factor, no low-dose oral prednisone
and DAS28-ESR as predictors of ultrasound-defined active
synovitis in RA patients in clinical remission
The multivariate logistic regression model designed to ex-
plore prognostic biomarkers for active synovitis included
variables with P ≤0.2 in the univariate analysis. Owing
to the strong correlation found between RF and several
serum biomarkers, RF titers were also included in the
model. After excluding any significant effect of RF, higher
serum bFGF, higher DAS28-ESR scores and no low-dose
oral prednisone were the best predictors of active syno-
vitis. Log2 bFGF, DAS28-ESR and no low-dose oral pred-
nisone adjusted odds ratio were 3.6 (95% CI: 1.5 to 12.1),
5.4 (95% CI: 1.3 to 31.3) and 5.1 (95% CI: 1.0 to 35.1),
respectively. The predictive indexes provided by the model
were: specificity 73.3%, sensitivity 72%, positive predictive
value 69.2%, negative predictive value 75.9% and area
under the receiver operating curve 81.5% (95% CI: 70.1 to
92.8%) (Figure 3).
Discussion
This study shows that nearly one-half of our patients with
RA in clinical remission, as defined by stringent clinical
criteria, had signs of active synovitis (SH grade ≥ 2 plus
PDUS signal). Clinically, these patients had significantly
higher disease activity and fewer were taking oral glu-
cocorticoids compared with patients with no criteria of
active synovitis. Although there were no differences in
acute phase reactants between groups, patients with active
synovitis had significantly higher serum levels of several
angiogenic factors thought to be relevant to RA pathoge-
nesis. A predictive index was developed for serum levels
of log2 bFGF, no low-dose oral prednisone treatment and
DAS28-ESR with an area under the receiver operating
curve of 0.815.
Studies have shown that more than 40% of RA patients
in clinical remission exhibit an increased PDUS signal,
which could explain why a proportion of these patients
develop radiographic progression during follow-up [3,5].
Table 3 Correlation between clinical, biological and ultrasound data and serum biomarkers
Ultrasound-defined synovitis SH ≥2 PDUS ≥1 ACPA titers RF titers CRP DAS28-ESR DAS28-CRP
R2 P valuea R2 P valuea R2 P valuea R2 P valuea R2 P valuea R2 P valuea R2 P valuea R2 P valuea
Activin A 0.234 0.085 0.228 0.093 0.164 0.231 0.409 0.002 −0.000 0.973 0.183 0.181 0.095 0.486 0.199 0.144
ANG 0.213 0.117 0.214 0.115 0.150 0.274 0.275 0.042 0.157 0.250 0.078 0.567 0.054 0.691 0.273 0.044
ANG-2 0.283 0.036 0.214 0.115 0.059 0.666 0.078 0.567 −0.130 0.314 0.081 0.553 0.001 0.989 0.189 0.165
ANG −0.210 0.109 −0.090 0.513 −0.295 0.029 −0.010 0.908 0.342 0.011 0.083 0.544 0.043 0.751 −0.250 0.064
ANGPTL4 −0.060 0.628 −0.010 0.920 −0.110 0.387 0.116 0.398 0.268 0.048 0.352 0.008 −0.190 0.160 −0.050 0.714
bFGF 0.366 0.006 0.265 0.050 0.264 0.051 0.335 0.012 1.000 0.094 0.096 0.485 −0.030 0.825 0.186 0.173
CXCL16 0.006 0.960 −0.040 0.738 0,066 0,629 0.251 0.064 −0.030 0.787 0.283 0.036 0.003 0.978 0.067 0.626
ENA-78 0.013 0.920 −0.060 0.639 0,019 0,890 0.164 0.231 0.083 0.544 0.035 0.795 0.400 0.002 0.000 0.968
GRO 0.128 0.350 0.079 0.565 −0,010 0,888 0.341 0.011 0.090 0.510 0.054 0.693 0.140 0.308 0.064 0.641
IL-17 F 0.023 0.868 0.050 0.713 0,042 0,756 0.206 0.130 0.083 0.573 0.358 0.007 −0.090 0.502 0.098 0.474
IL-18 0.250 0.065 0.154 0.259 0,188 0,169 0.323 0.016 0.537 <0.001b 0.190 0.163 −0.080 0.528 0.106 0.441
IL-20 0.227 0.095 0.193 0.156 0,133 0,332 0.409 0.002 0.306 0.023 0.097 0.481 0.049 0.719 0.195 0.153
IL-33 0.027 0.841 0.076 0.580 0,014 0,918 0.291 0.031 0.310 0.021 0.323 0.016 −0.160 0.220 0.107 0.433
MMP-2 0.301 0.025 0.268 0.048 0,178 0,192 0.368 0.006 0.454 <0.001b −0.000 0.988 0.002 0.987 0.166 0.225
PlGF 0.276 0.041 0.207 0.128 0,202 0,138 0.354 0.008 0.535 <0.001b 0.162 0.237 0.106 0.439 0.207 0.128
SDF-1 0.288 0.033 0.212 0.119 0,214 0,116 0.359 0.007 0.167 0.222 0.144 0.294 0.074 0.587 0.178 0.193
TGF-β1 0.232 0.088 0.298 0.027 0,085 0,534 0.042 0.758 0.263 0.052 0.217 0.110 −0.100 0.443 0.211 0.121
Tie-1 0.217 0.111 0.224 0.100 0,070 0,610 0.439 0.001 0.574 <0.001b 0.130 0.343 0.026 0.848 0.209 0.125
Tie-2 0.138 0.315 0.191 0.161 0,011 0,931 0.418 0.001 0.396 0.003 0.129 0.345 0.035 0.796 0.168 0.219
TNFα 0.101 0.462 0.163 0.232 −0,030 0,809 0.265 0.050 0.514 <0.001b 0.124 0.365 −0.040 0.750 0.078 0.569
VEGF 0.071 0.605 0.039 0.776 0,133 0,332 0.114 0.405 0.480 <0.001b 0.099 0.470 −0.288 0.033 −0.200 0.129
VEGFR-1 0.174 0.202 0.219 0.108 0,078 0,569 0.367 0.006 0.594 <0.001b 0.083 0.547 0.151 0.270 0.266 0.049
VEGF-D 0.324 0.016 0.239 0.078 0,157 0,251 0.327 0.015 0.264 0.051 0.118 0.388 −0.000 0.954 0.100 0.467
aSpearman’s nonparametric correlation. bP <0.01 adjusted for multiple testing (Bonferroni). ACPA, anti-cyclic citrullinated peptide/protein antibody; ANG, angiopoietin; ANGPTL4, angiopoietin-like protein-4; bFGF, basic
fibroblast growth factor; CXCL, CC-chemokine ligand; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ENA-78, epithelial cell-derived neutrophil-activating peptide-78; ESR, erythrocyte sedimentation rate;
GRO, growth-related oncogene; IL, interleukin; MMP, matrix metalloproteinase; PDUS, power Doppler ultrasound; PlGF, placental growth factor; RF, rheumatoid factor; SDF-1, stromal-cell derived factor-1; SH, synovial
hypertrophy; TGF-β1, transforming growth factor beta-1; Tie, tyrosine-kinase with immunoglobulin-like and endothelial growth factor-like domains; TNFα, tumor necrosis factor alpha; VEGF, vascular endothelial growth
factor; VEGFR, vascular endothelial growth factor receptor.
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Figure 3 Receiving operating curve from the model (basic fibroblast growth factor + Disease Activity Score in 28 joints + no oral
prednisone treatment). AIC, Akaike information criteria; AUC, area under the receiver operating curve; CI, confidence interval; DAS28, 28-joint
Disease Activity Score; ESR, erythrocyte sedimentation rate; FGF, fibroblast growth factor.
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ation both in improving the early diagnosis of RA and in
establishing true RA remission. SH scored by gray-scale
ultrasound seems less specific, with grade 1 being a fre-
quent finding in healthy controls [18]. Although there is
currently no clear definition of active synovitis on ultra-
sound, experts suggest including SH plus PDUS signal in
its definition [19]. We therefore defined active synovitis as
SH grade ≥2 with PDUS signal, which may be sufficiently
specific to capture only patients with potentially clinically
relevant synovitis. Currently there is no universally ac-
cepted combination of joints that should be included in
the ultrasound assessment of RA patients in remission
[20], and therefore we followed the recommendations of
Filer and colleagues [21] that suggest at least the wrist and
MCP joints of the dominant hand should be assessed. To
increase the sensitivity, we scored both hands (including
the wrist, MCP and proximal interphalangeal joints) and
knees.
Significantly fewer patients with ultrasound-defined ac-
tive synovitis were taking low-dose oral prednisone than
patients without active synovitis, confirming the results of
other studies that found low-dose oral steroids lead to a
greater probability of clinical remission and PDUSnegativity at 1 year of follow-up in a treat-to-target proto-
col in early-onset RA patients [22]. The question therefore
arises as to whether low-dose oral prednisone should be
added for patients in clinical remission with ultrasound-
defined active synovitis [23].
To our knowledge, no studies have assessed differences
in serum biomarkers of inflammation and disease activity
in patients with RA in clinical remission with and without
ultrasound-defined active synovitis. Using stringent ultra-
sonographic criteria, we identified a significant subgroup
of patients with subclinical activity. These patients were
characterized by higher DAS28 and increased serum levels
of several angiogenic factors (ANG-2, VEGF-D, PlGF,
SDF-1, bFGF and MMP-2) but there were no differences
in proinflammatory cytokines (TNFα, IL-6, IL-8, IL-17A,
IL-17 F, IL-18, IL-20, IL-23, IL-33). A model including
serum levels of bFGF, no low-dose oral prednisone treat-
ment and DAS28-ESR performed well in predicting active
ultrasonographic synovitis, with the predictive value being
independent of RF. These data suggest that diffe-
rent mechanisms are involved in clinical and subclinical
synovitis. An enhanced angiogenic response rather than
proinflammatory cytokines or systemic inflammation bio-
markers (CRP, ESR) might underlie subclinical synovitis.
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angiogenesis and SH, PDUS signal, ACPA or RF titers,
DAS28 and CRP were found, notably a strong positive
correlation between RF and ACPA titers and serum levels
of several biomarkers. However, the multivariate logistic
regression model showed that the association between
angiogenic biomarkers and active synovitis was not in-
fluenced by RF. Likewise, we found no significant dif-
ferences between the prevalence or titers of RF and ACPA
in patients with or without active synovitis, and higher
levels of angiogenic biomarkers in seronegative patients
with active synovitis. There was also a significant cor-
relation between ACPA titers and angiogenic biomarkers
in seronegative patients.
The strong correlation between some proinflammatory
cytokines (IL-17 F and IL-33) and CRP levels gives bio-
logical consistency to our results. Interestingly, all me-
diators that were significantly increased in patients with
ultrasound-defined active synovitis have previously been
implicated in the pathogenesis of arthritis, mainly in angio-
genesis and inflammation, which also gives physiopatho-
logical relevance to these findings. ANG-2 is expressed in
chronic synovitis, and is associated with increased prolife-
ration of synovial vessels that is reversed by anti-TNF
therapy [24]. PlGF is a specific ligand for VEGFR-1 and in-
duces the growth and migration of endothelial cells. PlGF
is highly expressed in the synovial tissue and fluid of RA
patients and its primary source is fibroblast-like synovio-
cytes [25]. SDF-1 (CXCL12) is a chemokine extensively
expressed by stromal cells in the synovial membrane in
RA and plays a role in angiogenesis [26]. Finally, bFGF
is mitogenic for endothelial cells and its overexpression
worsens inflammation and joint damage in antigen-
induced arthritis models in rats. However, experimental
work suggests that bFGF may contribute to arthritis by
increasing synovial angiogenesis, rather than through any
direct effect on inflammation [27].
bFGF was the biomarker that best identified US-defined
active synovitis, as it was also the only biomarker with
higher, almost significant, differences in active synovitis
both in SH grade ≥2 and in the PDUS signal, suggesting
that it may be a good biomarker of stromal cell activity.
We previously found that synovial stromal cells, fibro-
blast-like synoviocytes and mature vessels remain over-
represented in patients with a good clinical response to
TNFα inhibitors [28,29]. However, whether there is any
direct relationship between synovial stromal cells and
the angiogenic biomarkers we detected remains to be
determined.
This study has some limitations. The sample size and
the cross-sectional design limit the strength of the conclu-
sions. In addition, ultrasound scoring of the knee joint
and ultrasound-defined active synovitis are not validated.
However, we believe that the findings of this exploratorystudy provide new insights into the concept of clinical re-
mission in RA and open up new avenues in the search for
biomarkers that may be useful in the follow-up of RA pa-
tients in clinical remission.
Conclusion
This study found that 45% of RA patients with stringent
clinical remission criteria had ultrasound-defined active
synovitis. This group of patients had a higher DAS28
and fewer were taking oral prednisone compared with
patients without synovitis. These patients had signifi-
cantly higher levels of several angiogenic biomarkers,
especially bFGF, which correlated with different clinical
and serological variables. These findings suggest it may
be possible to find surrogate serum biomarkers of active
synovitis that could be useful in the follow-up of patients
with RA in remission.
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